Pharma industry fights back against more pricing negotiations

US healthcare lobbyist Vital Transformation has
released a document outlining objections to the expansion of drug
pricing policies under the Inflation Reduction Act (IRA).

One of US President Joe Biden’s signature policy
achievements, the IRA mandates a change to drug pricing which was
designed to enable savings for the federal health insurance
program Medicare.

The legislation, which has led to Medicare
administrators negotiating certain drug…

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

• All the news that moves the needle in pharma and biotech.
• Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
• Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

• Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
• Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
• Daily roundup of key events in pharma and biotech.
• Monthly in-depth briefings on Boardroom appointments and M&A news.
• Choose from a cost-effective annual package or a flexible monthly subscription.

No Byline Policy

Editorial Guidelines

Corrections Policy

Source